Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and heightens the oral absorbability and other such mucosal absorbability of a novel compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of conditions in which group 2 metabotropic glutamate receptors are said to participate, such as: schizophrenia, anxiety disorder and related conditions, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other such neuropsychiatric conditions； and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other such neurological conditions.提供使組群2代謝型麩胺酸受體作用劑之含氟胺基酸前驅藥化的以一般式(I)所表示之含氟胺基酸前驅藥、或其醫藥上所容許之鹽。更詳細係提供作為精神分裂症、焦慮障礙及其相關疾病、憂鬱症、雙極性情感疾患、癲癇、發展障礙、睡眠障礙等之精神神經疾病、以及藥物依賴症、認知障礙、阿滋海默病、亨氏舞蹈病、帕金森病、伴隨肌肉僵硬的運動障礙、腦缺血、腦死、脊髓障礙、頭部障礙等之神經學的疾病等與組群2代謝型麩胺酸受體有關疾病的治療劑或預防劑，使作用在組群2代謝型麩胺酸受體的親體化合物之經口吸收性等之黏膜吸收性增高，生體內暴露量增大的前驅藥。
